Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

21 Aug 2024

Abstract excerpt

RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The cooperative interplay between RAS and MYC constitutes a complex and multifaceted phenomenon, profoundly influencing tumor development. Together and individually, these two oncogenes regulate most, if not all, hallmarks of cancer, including cell death escape,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Histone Deacetylase Inhibitors Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39164274
DOI: 10.1038/s41392-024-01907-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancerPMID 39164274Read ↗

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Semantic proximity Read ↗

RAS: Striking at the Core of the Oncogenic CircuitrySemantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

The current state of the art and future trends in RAS-targeted cancer therapies.Semantic proximity Read ↗

RAS: Circuitry and therapeutic targeting.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?Semantic proximity Read ↗

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.Semantic proximity Read ↗

KRAS mutation: from undruggable to druggable in cancerSemantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal MicroenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.